News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Nathan H. Fowler, MD, MD Anderson Cancer Center

Articles by Nathan H. Fowler, MD, MD Anderson Cancer Center

ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

ASH 2020 Updates in Non-CLL B-Cell Lymphomas

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

ASH 2020 Updates in CLL

ByJennifer Woyach, MD, Ohio State University,Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Nathan H. Fowler, MD, MD Anderson Cancer Center,Sarah Rutherford, MD, Weill Cornell Medical College

January 22nd 2021

Treatment of R/R DLBCL: Beyond CAR T Therapy

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Phase 2B SADAL Trial in R/R DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

RE-MIND Study in R/R DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

L-MIND Study in R/R DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Standard of Care for Relapsed/Refractory DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Closing Thoughts on Treatment of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Improving Outcomes in Patients With R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Emerging Therapies for R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Safety and Efficacy of Oral Agents in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

CD19-Directed Therapies for Treatment of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

CAR T in R/R DLBCL: Safety and Patient Selection

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

ASCO 2020 Data: CAR T in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Role of CAR T-cell Therapy in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Treatment in Transplant-ineligible R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Prognosis of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Standard of Care for Treatment of DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Latest Updated Articles

Safety and Efficacy of Oral Agents in R/R DLBCL
Published: July 15th 2020 | Updated:
CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL
Published: September 22nd 2020 | Updated:
Emerging Therapies for R/R DLBCL
Published: July 15th 2020 | Updated:
RE-MIND Study in R/R DLBCL
Published: September 22nd 2020 | Updated:
CD19-Directed Therapies for Treatment of R/R DLBCL
Published: July 15th 2020 | Updated:
$ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas$
ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas
Published: January 22nd 2021 | Updated:

Trending on OncLive

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL